Traders Purchase Large Volume of Centessa Pharmaceuticals Call Options (NASDAQ:CNTA)

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) saw some unusual options trading on Tuesday. Traders purchased 2,994 call options on the stock. This is an increase of approximately 472% compared to the average volume of 523 call options.

More Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa for $38 per share in cash plus a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at roughly $6.3B up front and up to $7.8B including milestones; the transaction is framed as an expansion of Lilly’s neuroscience/sleep‑medicine pipeline. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Deal terms include the $38 cash upfront plus CVR milestones (up to $9) — investors are pricing some or all of the CVR into CNTA shares, which helps explain the stock trading above the $38 cash figure. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Positive Sentiment: Unusual options activity: large jump in call buying (nearly 3,000 calls traded, a ~472% spike vs. normal), signaling short‑term bullish speculation or hedging around the deal news.
• Neutral Sentiment: Analysts have mostly left ratings unchanged (Wolfe Research “peer perform”, Needham “hold”), suggesting the deal changes valuation more than near‑term fundamentals. Analyst coverage updates
• Neutral Sentiment: Trading metrics: unusually high share volume and CNTA trading near its 12‑month high, driven by the acquisition announcement and attendant positioning flows.
• Negative Sentiment: Shareholder litigation/investigations have been filed or announced (Ademi Firm and Halper Sadeh LLC) alleging Centessa shareholders may not be getting a fair price, which could lead to legal review, delay or pressure on deal terms. Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

Centessa Pharmaceuticals Stock Up 44.0%

NASDAQ:CNTA opened at $39.72 on Wednesday. The business’s fifty day moving average price is $26.29 and its 200 day moving average price is $25.24. The firm has a market capitalization of $5.80 billion, a price-to-earnings ratio of -21.70 and a beta of 1.55. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 1-year low of $9.60 and a 1-year high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). On average, sell-side analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CNTA. TD Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Needham & Company LLC reiterated a “hold” rating on shares of Centessa Pharmaceuticals in a report on Tuesday. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. Oppenheimer boosted their price target on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Finally, Truist Financial upped their price target on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, insider Iqbal J. Hussain sold 38,951 shares of Centessa Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider directly owned 57,645 shares in the company, valued at $1,449,771.75. The trade was a 40.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Karen M. Anderson sold 120,029 shares of the business’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.25, for a total value of $3,150,761.25. Following the sale, the insider directly owned 62,085 shares in the company, valued at $1,629,731.25. This trade represents a 65.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 349,073 shares of company stock valued at $9,429,412. Corporate insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Avoro Capital Advisors LLC grew its holdings in shares of Centessa Pharmaceuticals by 116.2% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after acquiring an additional 5,808,080 shares in the last quarter. EcoR1 Capital LLC raised its holdings in shares of Centessa Pharmaceuticals by 466.4% during the fourth quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock worth $77,906,000 after acquiring an additional 2,565,000 shares in the last quarter. Braidwell LP acquired a new stake in Centessa Pharmaceuticals during the fourth quarter valued at $54,730,000. Federated Hermes Inc. acquired a new stake in Centessa Pharmaceuticals during the third quarter valued at $42,429,000. Finally, Maverick Capital Ltd. purchased a new position in Centessa Pharmaceuticals in the fourth quarter valued at about $41,110,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.